Scarica l'app Stockscreener
127.27
0.41%
-0.53
Pre-mercato:
127.27
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Insmed Inc Borsa (INSM) Ultime notizie
Will Insmed Incorporated outperform the marketEarnings Growth Summary & Free Verified High Yield Trade Plans - Newser
Insmed Announces FDA Approval For Drug To Treat Chronic Lung Disease - MSN
What to do if you’re stuck in Insmed Incorporated2025 Stock Rankings & Weekly High Return Stock Opportunities - Newser
Is This a Bottoming Phase for Insmed Incorporated2025 Analyst Calls & Smart Money Movement Tracker - kangso.co.kr
Insmed (INSM) Gains As FDA Approves BRINSUPRI For New Market - Yahoo Finance
Non-Cystic Fibrosis Bronchiectasis Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring - Barchart.com
Insmed announces FDA approval of Brinsupri for NCFB - MSN
Is Insmed Incorporated stock entering bullish territoryTrade Volume Summary & Free Technical Pattern Based Buy Signals - Newser
Insmed's Brinsupri: A Game-Changer in the $3.7B Bronchiectasis Market and a Catalyst for Shareholder Value - AInvest
Insmed's Arikayce Approval and Implications of Brinsupri Approval - AInvest
Insmed: What The Approval Of Brinsupri Will Change? - Seeking Alpha
Is Insmed Incorporated stock forming a cup and handleWeekly Volume Report & Weekly Setup with High ROI Potential - thegnnews.com
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $139 to $173 - 富途牛牛
Insmed Director Makes a Major Move with Stock Sale! - TipRanks
Insmed's Stock Jumps 3.97% on FDA Approval, Hits $590M Top 500 Daily Volume - AInvest
Insmed Stock Surges 8.07% As Bullish Candlestick Pattern Signals Uptrend Continuation - AInvest
Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic - MSN
Stifel Raises Price Target for Insmed to $145 - AInvest
Insmed Stock Soars: What’s Next? - StocksToTrade
Truist Securities maintains Buy rating on Insmed with PT raised to $139. - AInvest
Pulmonary Hypertension associated with Interstitial Lung Disease Market to Witness Upsurge in Growth During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Truist Securities raises Insmed stock price target to $139 on brensocatib pricing - Investing.com Canada
Insmed price target raised to $145 from $121 at Stifel - TipRanks
Insmed price target raised to $139 from $126 at Truist - TipRanks
Insmed downgraded to Equal Weight from Overweight at Morgan Stanley - MSN
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $139 to $240 - 富途牛牛
Insmed stock price target raised to $240 from $120 at H.C. Wainwright - Investing.com Canada
Published on: 2025-08-14 16:09:54 - beatles.ru
Insmed stock price target raised to $173 from $109 at Wolfe Research - Investing.com Canada
Insmed Incorporated shares rise 3.37% premarket after multiple price target adjustments from UBS, RBC Capital, Mizuho, and Morgan Stanley. - AInvest
Insmed Incorporated May Be Forming Higher Low — Chartwatchers AlertJuly 2025 Breakouts & Real-Time Buy Signal Notifications - 선데이타임즈
Insmed Rises 0.71% as Volume Ranks 224th Post-FDA Approval Price Target Hiked to 240 - AInvest
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval - MSN
Insmed: HC Wainwright Raises PT to $240 from $120, Maintains Buy Rating - AInvest
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week - MSN
Insmed and VytlOne: A Groundbreaking Partnership in Rare Disease Innovation - AInvest
VytlOne Announces New Partnership with Insmed - Eastern Progress
Insmed stock downgraded at Morgan Stanley (INSM:NASDAQ) - Seeking Alpha
Insmed stock price target raised to $154 from $135 at TD Cowen on Brinsupri approval - Investing.com Canada
Goldman Sachs Raises Insmed Buy Rating to $142, PT from $114 - AInvest
Insmed stock price target raised to $138 from $120 at RBC Capital - Investing.com Canada
UBS Adjusts Insmed Price Target to $140 From $133, Maintains Buy Rating - MarketScreener
PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis - Yahoo Finance
Insmed wins FDA approval for future blockbuster Brinsupri - Yahoo Finance
Mizuho raises Insmed stock price target to $165 following Brinsupri approval - Investing.com Canada
Morgan Stanley Downgrades Insmed to Equal Weight From Overweight, Adjusts Price Target to $126 From $112 - MarketScreener
Mizuho Adjusts Price Target on Insmed to $165 From $130, Maintains Outperform Rating - MarketScreener
Mizuho Raises Price Target for Insmed (INSM) to $165 | INSM Stoc - GuruFocus
Insmed secures FDA approval for Brinsupri to treat NCFB - World Pharmaceutical Frontiers
Insmed stock price target raised to $140 from $130 at Wells Fargo - Investing.com Canada
Jefferies Raises Price Target on Insmed (INSM) to $148 | INSM Stock News - GuruFocus
Insmed gets first FDA approval for bronchiectasis - pharmaphorum
Insmed stock rating downgraded to Equalweight by Morgan Stanley - Investing.com Canada
Insmed (INSM) Receives Positive Analyst Ratings and Price Target Increases - AInvest
Insmed Price Target Raised to $140, Wells Fargo Keeps Overweight Rating. - AInvest
Insmed Trading Resumes: Investing with Confidence - AInvest
Wells Fargo Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $140 - 富途牛牛
Insmed (INSM) Surges 8.07% as Bullish Candlesticks and MACD Golden Cross Signal 65% Outperformance Probability - AInvest
Insmed Surges 8.07% on FDA Approval as $870M Trading Volume Hits Top 500 Daily Rank - AInvest
US FDA approves Insmed's drug as first treatment for a chronic lung disease - Reuters
Insmed’s Brensocatib Approval Boosts Market Potential and Stock Valuation - TipRanks
Wells Fargo Raises Price Target for INSM to $140, Maintains Over - GuruFocus
Insmed: Wells Fargo Reiterates Overweight, Raises PT to $140 from $130 - AInvest
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease - AOL.com
FDA Approves Insmed’s Brensocatib as First Therapy for Non-Cystic Fibrosis Bronchiectasis - geneonline.com
Insmed gains US approval of lung disease drug forecast to be blockbuster - BioPharma Dive
Brinsupri dose choice means bronchiectasis upside, Insmed says - BioWorld MedTech
Transcript : Insmed IncorporatedSpecial Call - MarketScreener
0.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):